Projects and registries
Ongoing projects and registries
TITLE
The COHESION Study: a European prospective cohort on eosinophilia and HES
PROMOTER/PI
Guillaume Lefèvre (PI) Lille University, France and Matthieu Groh, Hôpital Foch, Suresnes, France
AIM
To describe the frequency of the different clinical symptoms at diagnosis and during follow-up of hypereosinophilic syndromes (HES)
TITLE
Development of a new disease activity score for EGPA
PROMOTER/PI
Giacomo Emmi, University of Trieste, Italy and Augusto Vaglio, University of Firenze, Italy
AIM
To create a new tool to score disease activity in EGPA
TITLE
Overall long-term follow-up and damage accrual in EGPA across Europe
PROMOTER/PI
Aladdin Mohammad, Lund University, Sweden and Roberto Padoan, University of Padua, Italy
AIM
To developt a
TITLE
A survey to better understand the different approaches in diagnosing and treating EGPA
PROMOTER/PI
Paolo Cameli and Edoardo Conticini, Siena University Hospital, Siena, Italy
AIM
The aim of this study is to identify and explore the unmet needs in the management of eosinophilic granulomatosis with polyangiitis (EGPA), from both experts’ and patients’ perspectives, in order to improve care pathways and patient outcomes.
TITLE
MEPOLIZUMAB IN EGPA
PROMOTER/PI
Giacomo Emmi, University of Trieste, Italy and Alvise Berti, University of Trento, Italy and Roberto Padoan, University of Padua, Italy
AIM
1) the long-term follow-up of patients treated with Mepo (following the study published by Bettiol et al A&R 2022), also expanding the cohort of patients on Mepo 300mg (PI Giacomo Emmi, Trieste, Italy)
2) the effectiveness and safety of switching from Mepolizumab 100 to 300mg/4 weeks or vice versa (PI Giacomo Emmi, Trieste, Italy and Benjamin Terrier, Paris, France)
3) the effectiveness and safety of Mepo 300mg/4 weeks in newly diagnosed EGPA: The MEPEARL – MEPolizumab in EgpA Real Life study (PI Roberto Padoan, Padova, Italy)
4) the influence of anthropometric features on the response to Mepo (PI Alvise Berti, Trento, Italy)
TITLE
Effectiveness of Benralizumab after Mepolizumab treatment
PROMOTER/PI
Benjamin Terrier, Cochin Hospital, Paris, France and Giacomo Emmi, University of Trieste, Italy
AIM
To assess the effectiveness and safety on patients treated with Benralizumab after a previous Mepolizumab treatment
TITLE
Tezepelumab and EGPA
PROMOTER/PI
Benjamin Terrier, Cochin Hospital, Paris, France
AIM
This study will allow to collect retrospectively the off-label use of Tezepelumab (anti-TSLP) for the treatment of relapsing and/or refractory EGPA.
TITLE
Overlapping forms of PR3-ANCA EGPA/GPA
PROMOTER/PI
Benjamin Terrier, Cochin Hospital, Paris, France
AIM
This study will allow to better characterise the presentation, course and therapeutic management of overlapping forms of EGPA/GPA with PR3-ANCA
TITLE
Therapeutic approaches in myeloperoxidase (MPO)-associated interstitial lung disease (ILD): a multicentre study
PROMOTER/PI
Giacomo Emmi, University of Trieste, Italy
AIM
- To investigate the pattern of use of different treatments (immunosuppressants, anti-fibrotics or their combination) in patients with MPO-associated ILD
- To investigate the effectiveness of immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents in patients with MPO-associated ILD.
- To assess the rate of acute exacerbations following remission during treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
- To assess the occurrence of AAV during treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
- To assess potential differences in term of prognosis (hospitalization, death) in patients receiving immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
- To assess the safety of the treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents
TITLE
Efficacy and safety of Rituximab in EPGA patients with renal involvement
PROMOTER/PI
Dario Roccatello, University of Torino, Italy
AIM
TITLE
EGPA onset during biologic treatment for severe asthma
PROMOTER/PI
Marco Caminati, University of Verona, Italy
AIM
To assess the prevalence of EGPA onset during the course of biologic treatment with anti-IL-5, anti-IgE or anti IL-4/IL-13 treatments, prescribed for severe asthma.
TITLE
Effectiveness and Safety of Benralizumab in patients with EGPA: a retrospective study
PROMOTER/PI
Giacomo Emmi, University of Trieste, Italy and Augusto Vaglio, University of Firenze, Italy
AIM
To investigate retrospectively the efficacy and safety of benralizumab in EGPA patients.
TITLE
Eosinophilia-related temporal arteritis
PROMOTER/PI
Benjamin Terrier, Cochin Hospital, Paris, France
AIM
To specify the existence or not of an eosinophilic temporal arteritis, whose characteristics and prognosis could differ from giant cell arteritis. Also, the therapeutic management could be specified.
TITLE
CAPS-MEO study: Cryopyrin-associated periodic syndrome and eosinophilic meningitis
SCIENTIFIC DIRECTOR
Matthieu Groh, Internal Medicine Department, CEREO (Reference coordinating center of hypereosinophilic syndrome in France) – Foch Hospital and Cécilia Moscovici and Paul Legendre (PI, Le Mans hospital, France)
AIM
- Primary: to establish a retrospective cohort study of cases of eosinophilic meningitis associated with cryopyrin-associated periodic syndromes (CAPS).
- Secondary: to compare (clinical and genetic) data from collected cases with a cohort of CAPS patients followed in reference center.
INTERVIEW BY THE EXPERTS
